MarketPeel
Insider Trading Intelligence
MI

Mohamed Khairie Issa

INCY
EVP, HEAD OF US ONCOLOGY · INCYTE CORP · CIK 0002050035
FILING MIX · LIFETIME75%/25%
BUYS
6
SELLS
2
TOTAL VALUE
$2.07M
COMPANIES
1
ACTIVE SINCE
Jan 2025
HOLDINGS NOW
14,237
AVG SELL PX
$108.03
TRADE KIND
SHOWING 8 / 8
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
1 backtested trades · 8 horizons · 3 pending
Forward-return performance of every backtestable P/S trade by Mohamed Khairie Issa, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d1+100.00%-4.18%+0.11%-4.29%-4.29%
14d1+100.00%-5.34%-0.61%-4.73%-4.73%
30d1+100.00%-1.97%+0.15%-2.12%-2.12%
60d1+100.00%-12.18%-1.64%-10.54%-10.54%
90d1+100.00%-15.27%-4.40%-10.86%-10.86%
180d1(1 pending)
1y1(1 pending)
2y1(1 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
INCY · 14,237 shares · as of Jan 16, 2026
021,31342,62663,93985,2522026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2025
2025
2025
2025
2026
FLOW · 6 buys / 2 sellsCOVERAGE · 5 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
INCY
INCYTE CORP
PURCHASEGRANT
Stock grant
14,23714,237Jan 16, 2026Jan 21, 2026View →
INCY
INCYTE CORP
SALE10b5-1
10b5-1 plan
10,856$109.07$1.18M66,132Jan 7, 2026Jan 8, 2026View →
INCY
INCYTE CORP
SALE
EVP, Head of US Oncology
8,264$106.66$881.4K76,988Jan 6, 2026Jan 8, 2026View →
INCY
INCYTE CORP
PURCHASEGRANT
Stock grant
21,92321,923Jul 15, 2025Jul 17, 2025View →
INCY
INCYTE CORP
PURCHASEGRANT
Stock grant
19,73519,735Jul 15, 2025Jul 17, 2025View →
INCY
INCYTE CORP
PURCHASEGRANT
Stock grant
8,76985,252Jul 15, 2025Jul 17, 2025View →
INCY
INCYTE CORP
PURCHASEGRANT
Stock grant
27,81276,483Jun 30, 2025Jul 2, 2025View →
INCY
INCYTE CORP
PURCHASEGRANT
Stock grant
48,67148,671Jan 6, 2025Jan 8, 2025View →
Other insiders · INCY
Loading peer insiders…
About this filer
CIK 0002050035
ROLE
EVP, Head of US Oncology
PRIMARY
INCY
COMPANIES
1
ACTIVE SINCE
Jan 2025
MARKETPEEL · /INSIDER/0002050035DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback